InvestorBrandNetwork (IBN) Content Platform

Cboe Canada is welcoming back the Canadian Imperial Bank of Commerce (“CIBC”) for the listing of seven new Canadian Depositary Receipts (“CDRs”). According to the announcement, with these additional listings, CIBC has expanded its existing CDR line-up to 54 blue-chip U.S. public companies. CDRs, which were launched in 2021 and are available at a fraction of the price per share of the underlying stock, offer Canadian investors easier access to cross-border investing. The seven new CDRs now trading on Cboe Canada include BlackRock CDR (BLK: AQL), Constellation Brands CDR (STZ: AQL), Deere CDR (DEER: AQL), lululemon CDR (LULU: AQL), Palo Alto Networks CDR (PANW: AQL), ServiceNow CDR (NOWS: AQL) and Thermo Fisher CDR (TMO: AQL). The new tickers join other popular U.S. stocks already trading as CDRs on Cboe Canada.

“CDRs are a made-in-Canada success story demonstrating clear and continued investor interest as a result of the success of the existing lineup,” said Cboe Canada chief revenue officer Erik Sloane in the press release. “Through CDRs, investors gain easy access to some of the largest companies in the world. We are incredibly excited to continue the innovation and collaboration with CIBC as we work to meet the demands of Canadian investors.” 

To view the full press release, visit https://ibn.fm/j5e5K

About Cboe Canada

Cboe Canada is home to more than 260 unique listings, including Canadian Depositary Receipts (“CDRs”), ETFs from Canada’s largest ETF issuers and some of the most innovative Canadian and international growth companies. In Canada, Cboe consistently facilitates more than 20% of all volume traded in Canadian ETFs and more than 15% of all volume traded in Canadian-listed companies. Cboe Canada is Canada’s Tier 1 stock exchange for the purpose-driven innovation economy, providing a best-in-class listing experience for issuers that are shaping the economies of tomorrow. Fully operational since 2015, Cboe Canada lists investment products and companies seeking an internationally recognized stock exchange that enables investor trust, quality liquidity and broad awareness including unfettered access to market data. Cboe Canada is part of the Cboe Global Markets network, leveraging deep international expertise, industry-leading market intelligence and technology, and unparalleled service to deliver what stakeholders and the world need now and for the future. For more information, please visit www.Cboe.ca.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Canada Nickel (TSX.V: CNC) (OTCQX: CNIKF), a company that is advancing the next generation of nickel-sulphide projects, is reporting on the successful completion of its initial infill drilling at its wholly owned Bannockburn Property “B” Zone. The company also noted that its 2024 summer drill program will complete the drill program in preparation for an initial resource later this year. In addition, the company has scheduled a webcast and conference call to discuss its 2024 exploration program. The call is slated for Feb. 23, 2024, at 11 a.m. ET. Those interested can dial 416-764-8688 (local Toronto participants) or 1-888-390-0546 (toll free, North America). “The five Canada Nickel holes drilled to infill the ‘B’ Zone successfully intersected multihundred meter intervals of 0.27–0.29% nickel and, more importantly, each contained higher grade intervals of 0.3% nickel or better,” said Canada Nickel CEO Mark Selby in the press release. “The Bannockburn ‘B’ Zone has now been tested for its total 1.1-kilometer strike length with multiple intervals in excess of 0.3% nickel from both previous and current drilling. Bannockburn is highly complementary to our southern cluster of properties at Sothman, Midlothian, Van Hise and Powell.”

To view the webcast, visit https://ibn.fm/AhMyO

To view the full release, visit https://ibn.fm/wsr4R

About Canada Nickel Company Inc.

Canada Nickel is advancing the next generation of nickel-sulphide projects to deliver nickel required to feed the high-growth electric vehicle and stainless-steel markets. Canada Nickel has applied in multiple jurisdictions to trademark the terms NetZero Nickel(TM), NetZero Cobalt(TM) and NetZero Iron(TM), and is pursuing the development of processes to allow the production of net-zero carbon nickel, cobalt and iron products. Canada Nickel provides investors with leverage to nickel in low political-risk jurisdictions. Canada Nickel is currently anchored by its 100% owned flagship Crawford Nickel-Cobalt Sulphide Project in the heart of the prolific Timmins-Cochrane mining camp. For more information about the company, visit www.CanadaNickel.com.

NOTE TO INVESTORS: The latest news and updates relating to CNIKF are available in the company’s newsroom at https://ibn.fm/CNIKF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

CISO Global Inc. (NASDAQ: CISO), an industry leader as a managed cybersecurity and compliance provider (“MSSP”), has received an independent valuation of its initial IP Solutions Portfolio by a global leader in valuation, corporate finance and restructuring. According to the announcement, the valuation includes four IP solutions, which reflect the company’s push into delivering software-first solutions. The solutions include the company’s Skanda7 Breach Assessment Tool, CISO Edge Cloud Security Platform, CHECKLIGHT(R) Endpoint Security Monitoring and DISC VPN. Each of the solutions are powered by artificial intelligence (“AI”), neural nets and the latest generation of algorithms.

Skanda7 Breach Assessment Tool is a next-generation analysis tool that looks beyond vulnerabilities found by most other technology to deliver continuous security assessments. CISO Edge Cloud Security Platform is a cloud-first security solution focused on protecting users from untrusted, malicious online threats. CHECKLIGHT Endpoint Security Monitoring is a powerful security monitoring software that detects possible threats to networks and provides advance alerts. DISC VPN is a token exchange-protected remote access solution that replaces traditional VPN connections with enhanced security and access verification.

“This valuation is representative of our commitment to our clients, is unparalleled, and we continue to innovate by delivering high value, software-first solutions based on AI, ML and advanced algorithms,” said CISO Global CEO David Jemmett in the press release. “By leveraging the latest technology advances coupled with our threat intel team, we are providing unique and actionable intelligence to our clients. These solutions are now being deployed and are strengthening the security posture of our clients. CISO Global will continue to disrupt the status quo by delivering new IP already in development.”

To view the full press release, visit https://ibn.fm/n4Dk6

About CISO Global Inc.

CISO Global is based in Scottsdale, Arizona, and is a top 25 managed cybersecurity and compliance services provider that is delivering innovative solutions through its newly developed artificial intelligence (“AI”) and machine-learning (“ML”)-powered product portfolio. The company protects the most demanding businesses and government organizations against continuing and emerging security threats and ensures their compliance obligations are being met.mFor more information about the company, visit www.CISO.inc.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Lottery.com (NASDAQ: LTRY, LTRYW), a leading online lottery services provider, has announced that the legal action alleging proxy misstatements filed in federal court by Woodford Eurasia Assets Ltd against Lottery.com and the individual members of the company’s board of directors has been voluntarily dismissed without prejudice by Woodford. The notice of voluntary dismissal was filed by Woodford in the United States District Court for the District of Delaware on Feb. 14, 2024, in Case No. 23-1317-GBW. “We are pleased to put this matter behind us. This resolution allows us to focus on our mission to offer innovative solutions in the lottery industry and to transform the sports media and entertainment arena with sports.com. We can now get back to focusing on providing value for our customers and stakeholders,” said Matthew McGahan, chairman of Lottery.com and Sports.com. “We remain committed to operating with the highest standards of integrity and look forward to continuing our work in revolutionizing the lottery and sports media experience worldwide. I would like to express my gratitude to our legal advisors, my fellow board directors and all those who have supported the company through this process.”

To view the full press release, visit https://ibn.fm/Wq0ET

About Lottery.com Inc.

Lottery.com is a leading technology company that is transforming how, where and when lottery is played. Its engaging mobile and online platforms enable players and commercial partners located in the United States and internationally to remotely purchase legally sanctioned lottery games. Fans and subscribers look to Lottery.com for compelling, real-time results on more than 800 lottery games from more than 40 countries. Additionally, through WinTogether.org, Lottery.com is fundamentally changing how non-profit donors are incentivized to action by gamifying charitable giving. In all that it does, Lottery.com’s mission remains the same: an uncompromising passion to innovate, grow a new demographic of enthusiasts, deliver responsible and trusted solutions, and promote community and philanthropic initiatives. For more information about the company, visit www.Lottery.com.

NOTE TO INVESTORS: The latest news and updates relating to LTRY are available in the company’s newsroom at https://ibn.fm/LTRY

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

• The Activist Investor Conference will take place on March 21, 2024, at 237 Park Avenue, one of Manhattan’s premiere meeting venues
• The 14th annual edition of the conference features investors, corporate board members and governance experts, advisory firms, proxy solicitors and finance professionals who will delve into the latest trends within shareholder activism
• This year’s conference features a number of keynote presentations by experts in the field, including Patrice Bonfiglio, Sean Donohue, and Jon Feldman

Shareholder activism emerged in the 1970s and 1980s as a tool to drive the process of price formation, improve corporate governance and defend minority shareholder interests. Today, in a market environment characterized by a surge in the number of passive investors and a reduction in the diversity of research and market participants, the importance of shareholder activism may be greater than ever.

Corporate engagement and shareholder activism has become increasingly crucial within the context of…

Read More>>

For additional details about the Activist Investor Conference, including registration, visit: https://www.activistinvestorconference.com.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Lucy Scientific Discovery (NASDAQ: LSDI), a company dedicated to advancing the understanding and applications of psychotropic medicines, improving mental-health outcomes, and enhancing well-being for individuals worldwide announces will affect a one-for-ten reverse split of its common shares. According to the announcement, LSDI is hoping the reverse split will help the company regain compliance with NASDAQ’s $1 minimum bid price requirement. The reverse share will become effective on Feb. 26, 2024, with shares expected to begin trading on the split-adjusted basis on the NASDAQ Stock Exchange. “On the effective date, every 10 issued and outstanding shares of the company’s common stock will be converted automatically into one share of the company’s common stock without any change in the par value per share,” stated Lucy Scientific Discovering in the press release.

To view the full press release, visit https://ibn.fm/CKzqI

About Lucy Scientific Discovery Inc.

Lucy Scientific Discovery is a NASDAQ-listed company with holdings and operations in a variety of psychotropic businesses. Lucy Scientific Discovery is dedicated to advancing the understanding and applications of psychotropic medicines, improving mental-health outcomes and enhancing well-being for individuals worldwide. For more information, visit the company’s website at www.LucyScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to LSDI are available in the company’s newsroom at https://ibn.fm/LSDI

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is reporting financial results and business updates for the third fiscal quarter of 2024, the period ended Dec. 31, 2023. Highlights of the report include the company receiving a patent from the European Patent Office covering a method for treating pain in humans and a patent from the Divisional Direction of Patents, Mexico, for a treatment of Alzheimer’s disease; in addition, the company entered an agreement with the University of Los Andes to research and study initiatives in artificial intelligence and machine learning. Financial numbers of note include approximately $204 thousand in revenue for the quarter, a 38% decrease compared to the three months ended Dec. 31, 2022, and an estimated $1.05 million in revenues generated for the nine months ended Dec. 31, 2023, an increase of 40% compares to the same period in 2022; selling, general and administrative expenses for the period reached approximately $2.2 million; research and development expenses came in at approximately $903 thousand; and net loss for the three-month period was an estimated $5.5 million, or $0.09 per share, compared to some $2.2 million, or $0.04 per share, for three months ended Dec. 31, 2022.

The report indicated current cash and cash equivalents is sufficient to support operations beyond the 12 months following the date the consolidated financial statements and footnotes were issued. “We are proud to share that our company is making progress with our lead asset, IGC-AD1, which is currently in a phase 2b trial for the treatment of agitation in dementia due to Alzheimer’s,” said IGC Pharma CEO Ram Mukunda in the press release. “We are working hard to obtain interim results in 2024. We estimate that in North America and Europe about 11 million Alzheimer’s patients have neuropsychiatric symptoms including agitation. With modest pricing and conservative market penetration IGC-AD1 can potentially be a blockbuster drug.”

To view the full press release, visit https://ibn.fm/XNQpz

About IGC Pharma

IGC Pharma is pursuing innovative solutions to fight Alzheimer’s disease and related challenges. The company’s portfolio comprises five assets, all with a singular mission: to transform the landscape of Alzheimer’s treatment. IGC-AD1 and LMP target neuroinflammation, Aβ plaques and neurofibrillary tangles. IGC-AD1 is currently in a phase 2b clinical trial for agitation in dementia due to Alzheimer’s. TGR-63 targets Aβ plaque to disrupt the progression of Alzheimer’s disease. IGC-M3 targets the inhibition of Aβ plaque aggregation with the potential to create a profound impact on early-stage Alzheimer’s. IGC-1C targets tau and neurofibrillary tangles as a forward-thinking approach to Alzheimer’s therapy. In parallel, IGC Pharma is at the forefront of generative AI development, with projects including clinical trials, early detection of Alzheimer’s and drug interactions with cannabinoids. For more information, visit the company’s website at www.IGCInc.us.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Tonix Pharmaceuticals Holding (NASDAQ: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced participation at the 2024 BIO CEO & Investor Conference. According to the announcement, Tonix’s President and CEO, Seth Lederman, M.D., will present at the event, with his presentation scheduled for February 26, 2024, at 1:30 p.m. ET in New York City.

To view the full press release, visit https://ibn.fm/p9Sx1

About Tonix Pharmaceuticals Holding Corp.

Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system disorders. Tonix’s priority is to submit a New Drug Application (“NDA”) to the FDA for Tonmya, which has completed two positive Phase 3 studies for the management of fibromyalgia. Tonix intends to meet with the FDA in the first half of 2024 and submit an NDA for the approval of Tonmya for the management of fibromyalgia in the second half of 2024. TNX-102 SL is being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition, and topline results from a proof-of-concept study were reported in the third quarter of 2023. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the first quarter of 2024. Tonix’s rare disease development portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome (“PWS”). TNX-2900 has been granted Orphan Drug designation by the FDA and an investigational new drug (“IND”) application has been cleared to support a Phase 2 study in PWS patients. Tonix’s immunology development portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (“CD40L” or “CD154”) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-801 was initiated in the third quarter of 2023. Tonix’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800, in development as a vaccine to protect against COVID-19. During the fourth quarter of 2023, TNX-1800 was selected by the U.S. National Institutes of Health (“NIH”), National Institute of Allergy and Infectious Diseases (“NIAID”) Project NexGen for inclusion in Phase 1 clinical trials. The infectious disease development portfolio includes TNX-3900 and TNX-4000, which are classes of broad-spectrum small molecule oral antivirals. Tonix Medicines, the company’s commercial subsidiary, markets Zembrace(R) SymTouch(R) (sumatriptan injection) 3 mg and Tosymra(R) (sumatriptan nasal spray) 10 mg under a transition services agreement with Upsher-Smith Laboratories, LLC from whom the products were acquired on June 30, 2023. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. For more information about Tonix, visit www.tonixpharma.com.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal-pest populations, will be reporting its financial results for its fourth quarter and fiscal year 2023, or the period ended Dec. 31, 2023. The company has scheduled the release of the report for after market close on Feb. 21, 2024. In addition to releasing the report, the company has scheduled a teleconference for that same date to review the report; the call will begin at 5 p.m. ET. Those interested in participating in the call can dial (844) 308-3351 or (412) 317-5407. A replay of the teleconference will be available for seven days following the event; those interested in viewing the replay can dial (877) 344-7529 or (412) 317-0088, using replay access code 3232725.

To view the live webcast, visit https://ibn.fm/EI3H4

To view the full press release, visit https://ibn.fm/1WmVL

About SenesTech Inc.

SenesTech is committed to improving the health of the world by humanely managing animal-pest populations through fertility control. SenesTech is an expert in fertility control to manage animal pest populations. The company invented ContraPest, the only U.S. EPA-registered contraceptive for male and female rats, and Evolve, an EPA-designated minimum-risk contraceptive currently offered for rats. ContraPest and Evolve fit seamlessly into all integrated pest-management programs, significantly improving the overall goal of effective pest management. The company strives for clean cities, efficient businesses and happy households by providing a product designed to be humane, effective and sustainable. For more information about the company, please visit www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Battery Mineral Resources (TSX.V: BMR) (OTCQB: BTRMF) (“BMR”), a company providing shareholders exposure to the global megatrend of electrification while being focused on growth through cash flow, exploration and acquisitions in favorable mining jurisdictions, has closed the third and final tranche of a previously announced private placement of senior unsecured convertible debentures. The company raised gross proceeds of US$1,000,000 (C$1,349,300) from the third tranche, bringing the aggregate raised under the offering to US$4,285,000 (C$5,881,091). Battery Mineral Resources had raised gross proceeds of US$1,370,000 (C$1,871,557) from the first tranche of the offering, which closed on Oct. 19, 2023, and gross proceeds of US$1,915,000 (C$2,660,234) from the second tranche, which closed on Nov. 3, 2023. According to the announcement, the company intends to apply the proceeds from the debentures toward working capital and the restart of copper concentrate production at its Punitaqui copper project in Chile.

To view the full press release, visit https://ibn.fm/zv3Tz

About Battery Mineral Resources Corp.

Battery Mineral Resources is a battery minerals company providing shareholders exposure to the global megatrend of electrification while being focused on growth through cash flow, exploration and acquisitions in favorable mining jurisdictions. Battery Mineral’s mission is the discovery, acquisition and development of battery metals (namely cobalt, lithium, graphite and copper) in North America, South America and South Korea, and to become a premier and responsible supplier of battery minerals to the electrification marketplace. BMR is currently pursuing a near-term resumption of operations of the Punitaqui Mining Complex, a past copper-gold-silver producer in the Coquimbo region of Chile. BMR is the largest mineral claim holder in the historic Gowganda Cobalt-Silver Camp in Ontario, Canada, and continues to pursue a focused program to build on the recently announced, +1-million-pound high-grade cobalt resource at McAra. In addition, Battery Mineral owns 100% of ESI Energy Services Inc. (including ESI’s wholly owned USA operating subsidiary, Ozzie’s, Inc.), a profitable mainline pipeline and renewable energy equipment rental and sales company with operations in Alberta, Canada, and Arizona, USA. Battery Mineral Resources is based in Canada and its shares are listed on the TSX Venture Exchange under the symbol BMR and on the OTCQB under the symbol BTRMF. Further information about BMR and its projects can be found at www.BMRCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to BTRMF are available in the company’s newsroom at https://ibn.fm/BTRMF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Infobird (NASDAQ: IFBD), a software-as-a-service provider of AI-powered customer engagement solutions in China, is announcing that its management team has decided not to carry out any financing activities in the next three months. The company has raised some operating funds in previous financing activities that will help Infobird expand its business. The decision follows consultations with previous investors and is intended to better protect the interests of the company’s small and medium shareholders, Infobird said in the announcement. Infobird’s management team expressed its appreciation for potential investors’ continued attention and interest in the company.

To view the full press release, visit https://ibn.fm/7sYm3

About Infobird Co. Ltd.

Infobird, headquartered in Hong Kong, is a software-as-a-service provider of innovative AI-powered, or artificial intelligence-enabled, customer engagement solutions. For more information, visit Infobird’s website at www.Infobird.com.

NOTE TO INVESTORS: The latest news and updates relating to IFBD are available in the company’s newsroom at https://ibn.fm/IFBD

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Lottery.com (NASDAQ: LTRY), a leading online lottery services provider, has acquired S&MI Ltd., or SportLocker. According to the announcement, with the stock-based acquisition complete, SportLocker will be rebranded as Sports.com and will immediately launch as a premier platform for sports fans worldwide. The company noted that the transition marks “a pivotal leap in Sports.com’s evolution as the next-gen digital sports entertainment space.” The new platform will feature innovative community-driven aspects along with expansive content and technology. The company plans to roll out Sports.com in the United States and Europe first, along with concentrated efforts in the Middle East. Ultimately, the strategy includes a global expansion targeting high-energy sports such as soccer, motor racing, football, baseball, basketball, MMA, boxing, cricket, golf, field and ice hockey, and tennis. This global direction underscores Sports.com’s commitment to driving growth in higher-value territories and underserved markets. The announcement noted that a core strategy behind the acquisition of SportLocker and subsequent rebranding includes leveraging already-established partnerships with mobile network operators (“MNOs”) to offer localized branded sports content services.

“This acquisition is of great strategic importance to our group, and we are delighted to unveil Sports.com to the world with a revolutionary vision that will transform how fans engage with sports,” said Lottery.com chair and CEO Matthew McGahan in the press release. “By integrating SportLocker’s robust MNO partnerships, localized content services and community-focused features with enhanced content and technology, we are creating a dynamic ecosystem where fans can not only consume sports but also connect and create in ways never before offered to the mass of sports fans worldwide. We are positioning Sports.com to offer sports fans an unparalleled year-round experience. The introduction of our media platform is just a glimpse of how we intend to bring fans closer to the sports they love.”

To view the full press release, visit https://ibn.fm/NOLQZ

About Lottery.com Inc.

Lottery.com is a leading technology company that is transforming how, where and when lotteries are played. Its engaging mobile and online platforms enable players and commercial partners located throughout the United States and other countries to remotely purchase legally sanctioned lottery games. Fans and subscribers look to Lottery.com for compelling, real-time results on more than 800 lottery games from more than 40 countries. Additionally, through WinTogether.org, Lottery.com is fundamentally changing how nonprofit donors are incentivized to action by gamifying charitable giving. In all that it does, Lottery.com’s mission remains the same: an uncompromising passion to innovate, grow a new demographic of enthusiasts, deliver responsible and trusted solutions, and promote community and philanthropic initiatives. To learn more about the company, visit www.Lottery.com.

NOTE TO INVESTORS: The latest news and updates relating to Lottery are available in the company’s newsroom at https://ibn.fm/Lottery

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Datasea (NASDAQ: DTSS) is a Nevada incorporated digital technology corporation engaged in innovative business segments for intelligent acoustics and 5G multimodal communication technology in China. The company has announced that on Feb. 2, 2024, Guozhong Times (Beijing) Technology Ltd., a subsidiary of the Chinese operating company contractually controlled by Datasea, has entered into a cooperation agreement with Hangzhou Chongda Technology Co., Ltd. (“Chongda”) to increase the sales of 5G multimodal communication services in China. “We are pleased to enter into this new collaboration as it will help to identify potential customers that need our 5G multimodal communication delivery services and enable us to quickly roll out our unique platform to new customers,” said Datasea CEO Zhixin Liu. “We believe that Datasea can capitalize on more opportunities of this nature to generate revenue and it is in line with our mission to become a leading provider of digital technology solutions as well as our unwavering commitment to the 5G multimodal communication market in China. At the same time, the company is negotiating with major potential clients of 5G multimodal communication services and expects to reach more agreements.”

To view the full press release, visit https://ibn.fm/o3rFE

About Datasea Inc.

Datasea is a leading provider of products, services and solutions for enterprise and retail customers in innovative industries, intelligent acoustics and 5G multimodal communication, especially focusing on ultrasonic, infrasound and directional sound technology. The company’s advanced R&D technology serves as the core infrastructure and backbone for its products. Its 5G multimodal communication segment operates on a cloud platform based on AI. Datasea leverages cutting-edge technologies in intelligent acoustics, utilizing ultrasonic sterilization to combat viruses and prevent human infections, and is also developing innovations in directional sound and medical ultrasonic cosmetology. In July 2023, Datasea established a wholly owned subsidiary, Datasea Acoustics LLC, in Delaware, in a strategic move to mark its global presence. This underlies Datasea’s commitment to intelligent acoustics and its intent to offer leading edge acoustic solutions to the U.S. market. For additional information about the company, visit www.DataseaInc.com.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Pressure BioSciences (OTCQB: PBIO), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly enabling, pressure-based instruments and nanoemulsion products and services for the health and wellness, food and beverage, pharmaceutical, and other industries, has achieved a significant milestone in its accelerating growth journey. The company has consolidated its Boston-area operations, uniting all of its personnel into a single Boston location. The new facility includes product manufacturing suites, an advanced R&D laboratory, state-of-the-art equipment manufacturing, formulation services and a demo lab designed to showcase PBIO’s cutting-edge UltraShear technology platform, allowing stakeholders to witness the platform’s potential firsthand. According to the announcement, consolidating R&D with all other departments of the company will streamline and achieve new production efficiencies as well as reduce costs and foster innovation by creating a collaborative work environment. “We are very excited about the opportunities this consolidation and expansion presents,” said Pressure BioSciences director of business development Ken Micciche in the press release. “The move reinforces our commitment to accelerating development and production capabilities, delivering exceptional products and services, advancing the field of high-pressure nanotechnology, fostering collaborations with academic and industry partners, and supporting our expected explosive growth in the direct-to-consumer area, led by our newly acquired subsidiary company Uncle Bud’s Health & Wellness.”

To view the full press release, visit https://ibn.fm/vT2t3

About Pressure BioSciences Inc.

Pressure BioSciences is a global leader in providing innovative, broadly enabling, high-pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical and agrochemical, as well as food and beverage manufacturing. PBIO’s patented enabling platform, Pressure Cycling Technology (“PCT”), utilizes alternating cycles of pressure to control biomolecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counterbioterrorism applications. The company’s patented BaroFold(TM) technology platform allows PBIO to enter the biopharma contract services and GMP manufacturing equipment sector. PBIO has also developed the scalable and high-efficiency pressure-based UltraShear Technology(TM) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room-temperature-stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. The company’s commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to its customers. For more information, visit the company website at www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Vstock Transfer, a premier stock-transfer agent serving nearly 1,000 issuers, is expanding its services designed specifically for initial public offerings (I”POs”) and existing public companies. Vstock’s expanded offerings include shareholder meeting services, virtual meeting administration, proxy tabulation, document web hosting, inspector of election services, and notice and access material distribution. The new offerings reflect the company’s mission, which is to serve as a robust resource for companies and shareholders with a comprehensive suite of services designed to streamline processes, ensure compliance and foster confidence at every stage of the capital markets journey. The announcement noted the company’s introduction of a a comprehensive, compliant and user-friendly IR widget investor solution that supports better communication with current and potential investors through corporate websites. The platform streamlines a variety of financial data, including stock price, volume, dividends, earnings reports and press releases, in real-time or with minimal delay.

“Even after 12 years, we are still innovating and rolling out new technology,” said Vstock Transfer CEO Yoel Goldfeder in the press release. “Our team is dedicated to supporting management teams and shareholders throughout the entire meeting process, from planning and execution to participation and post-meeting follow-up.”

To view the full press release, visit https://ibn.fm/UcjbS

About Vstock Transfer

Vstock Transfer is an SEC-registered stock transfer firm serving private companies, IPOs and issuers listed on NYSE American, NASDAQ and OTC markets. Vstock Transfer is owned and managed by attorneys and a team of professionals who have spent their careers working with issuers on all aspects of initial public offerings, follow-on public offerings, private placements, Reg A, proxy solicitations, DTC eligibility, SPACs, reverse mergers and stock transfers. For more information about the company, please visit www.VStockTransfer.com.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, today announced its entry into a distribution agreement with Q-chem, a pest control product supplier in the Netherlands. SenesTech has developed and is commercializing a proprietary technology for managing animal pest populations, primarily rat populations, through fertility control. “Q-chem is a perfect partner for SenesTech as we begin our expansion into Europe, and Evolve(TM) fits into their portfolio perfectly,” said Joel Fruendt, SenesTech’s president and CEO. “They have a stated focus on new, environmentally friendly and sustainable products for pest control, and they distribute pest control products in the Netherlands and specifically non-biocidal products throughout Europe.”

To view the full press release, visit https://ibn.fm/aZdFI

About SenesTech Inc.

SenesTech is committed to improving the health of the world by humanely managing animal pest populations through fertility control. The company is an expert in fertility control to manage animal pest populations. It invented ContraPest(R), the only U.S. EPA-registered contraceptive for male and female rats, and Evolve(TM), an EPA-designated minimum risk contraceptive currently offered for rats. ContraPest and Evolve fit seamlessly into all integrated pest management programs, significantly improving the overall goal of effective pest management. SenesTech strives for clean cities, efficient businesses and happy households – with a product designed to be humane, effective and sustainable. For more information about the company, visit www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Knightscope (NASDAQ: KSCP), a leading innovator in robotics and artificial intelligence (“AI”) technologies focused on public safety, has deployed two more of its K5 Autonomous Security Robots (“ASRs”). The robots feature KSCP’s proprietary AI software, which provides for enhanced safety measures. The robots were sent to patrol a Washington casino and a security-services company; the security-services company recently became a reseller in the Knightscope Authorized Partner (“KAP”) program.

“The robot’s commanding size along with its conspicuous lighting, strobe lights, broadcast messages and patrol sounds, effectively deter illicit activities, while its sensors gather evidentiary-quality video and publicly available data to aid investigations,” said the company in the press release. “The robots also provide a unique guest experience with branded graphics, a client-chosen voice for custom audio broadcast messaging and improved access to emergency services.”

Knightscope’s KAP program is offered to a limited number of established resellers that are focused on serving U.S. customer facilities. According to the company, approved KAPs can identify end users best suited for Knightscope’s technologies and generate contracts quickly.

To view the full press release, visit https://ibn.fm/RP2bY

About Knightscope, Inc.

Knightscope builds cutting-edge technologies to improve public safety. The company’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Safety Shot (NASDAQ: SHOT), a wellness and functional beverage company, has a new brand ambassador. The company announced that American professional skateboarder and businessperson Danny Way has joined Safety Shot. In his new brand ambassador role, Way will work to increase awareness of the world’s first patented wellness beverage designed to help people feel better faster by reducing blood alcohol content while also boosting clarity and overall mood. Way stated that “having survived and thrived through some serious hardship early in my life and injuries during my skateboarding career, believe me, I know about recovery.” He noted that he is a full supporter of Safety Shot’s mission and will be “sharing my love for it with anyone who wants to get sharper and energized.” At age 15, Way became the youngest person to win a pro vert skateboarding contest at the World Skateboard Association Pro Vert Contest; he then went on to become an award-winning professional skateboarder. Safety Shot is the first-ever patented wellness beverage that reduces blood alcohol content in as little as 30 minutes. According to the company, the game-changing beverage helps process alcohol more efficiently, helps the body maintain hydration and improves the overall feeling of well-being through nootropics and vitamins. “As a record-breaking experimentalist skateboarder and businessperson, Danny exemplifies Safety Shot’s thirst for life and resilience,” said Safety Shot CRO Josh Wagner in the press release. “We welcome him to our growing band of brand ambassadors who span a broad cultural swath with global reach and impact.”

To view the full press release, visit https://ibn.fm/KUshg

About Safety Shot

Safety Shot, a wellness and functional beverage company, is set to launch Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity and overall mood. Safety Shot is available for purchase online at DrinkSafetyShot.com and Amazon. The company plans to launch business-to-business sales of Safety Shot to distributors, retailers, restaurants and bars in the first quarter of 2024. For more information about the company, visit www.SafetyShotHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to SHOT are available in the company’s newsroom at https://ibn.fm/SHOT

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”)). The company today announced its entry into a definitive agreement for the immediate exercise of an outstanding common stock purchase warrant held by an institutional investor to purchase an aggregate of 980,393 shares of common stock for gross proceeds to Vivos of approximately $4.0 million. As part of the transaction, the investor agreed to exercise the existing warrant (originally issued in November 2023 with an exercise price of $3.83 per share) at a revised exercise price of $4.02 per share. The resale of the shares of common stock issuable upon exercise of the warrant were registered per an effective registration statement on Form S-1. In consideration for the immediate exercise of the existing warrant for cash, Vivos agreed to issue to the investor two new unregistered warrants, each to purchase 735,296 shares of common stock (or an aggregate of 1,470,592 shares) at an exercise price of $5.05 per share. The new warrants will be exercisable immediately upon issuance. Such warrants are identical, with exception of one warrant having a term of five years and the second a term of eighteen months. A.G.P./Alliance Global Partners is acting as the exclusive financial advisor in connection with the offering.

To view the full press release, visit https://ibn.fm/1voaI

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (“OSA”) and snoring in adults. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild-to-severe OSA. It has proven effective in approximately 40,000 patients treated worldwide by more than 1,800 trained dentists. The Vivos Method includes treatment regimens that employ the proprietary CARE appliance therapy and other modalities that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and/or palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild-to-severe OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using The Vivos Method. For more information, visit www.Vivos.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Tonix Pharmaceuticals Holding (NASDAQ: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, is announcing that people who are suffering from fibromyalgia pain but do not want to risk addiction to an opioid are closer to a new option for treatment. According to the announcement, the company announced positive Phase 3 study results for its non-opioid investigational drug candidate Tonmya or TNX-102 SL in late December. The results showed that Tonmya lowered the characteristic widespread pain in fibromyalgia, indicating that it could potentially be the first in a new class of painkillers to be approved for use in fibromyalgia. In addition, the experimental medicine improved sleep and fatigue in fibromyalgia. Tonix intends to submit a New Drug Application (“NDA”) with the FDA in the second half of the year and expects a decision in 2025.

Additionally, Tonix is featured in an FN Media Group News Commentary. The commentary covered Tonix’s recent news, including the announcement that the company has engaged Rho, Inc., a global contract research organization (“CRO”), to support its preparation and planned submission of its New Drug Application (“NDA”) to the U.S. Food and Drug Administration. The NDA will seek FDA approval for Tonmya(TM) (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia. The commentary also highlighted a recent key opinion leader (“KOL”) webinar held to discuss the positive Phase 3 data of Tonmya for the management of fibromyalgia and the path to file for FDA approval in the second half of 2024.

To view the full press releases, visit https://ibn.fm/t9IVu  and https://ibn.fm/GQzjA

About Tonix Pharmaceuticals Holding Corp.

Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system disorders. Tonix’s priority is to submit a New Drug Application (“NDA”) to the FDA for Tonmya, which has completed two positive Phase 3 studies for the management of fibromyalgia. Tonix intends to meet with the FDA in the first half of 2024 and submit an NDA for the approval of Tonmya for the management of fibromyalgia in the second half of 2024. TNX-102 SL is being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition, and topline results from a proof-of-concept study were reported in the third quarter of 2023. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the first quarter of 2024. Tonix’s rare disease development portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome (“PWS”). TNX-2900 has been granted Orphan Drug designation by the FDA and an investigational new drug (“IND”) application has been cleared to support a Phase 2 study in PWS patients. Tonix’s immunology development portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (“CD40L” or “CD154”) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-801 was initiated in the third quarter of 2023. Tonix’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800, in development as a vaccine to protect against COVID-19. During the fourth quarter of 2023, TNX-1800 was selected by the U.S. National Institutes of Health (“NIH”), National Institute of Allergy and Infectious Diseases (“NIAID”) Project NexGen for inclusion in Phase 1 clinical trials. The infectious disease development portfolio includes TNX-3900 and TNX-4000, which are classes of broad-spectrum small molecule oral antivirals. Tonix Medicines, the company’s commercial subsidiary, markets Zembrace(R) SymTouch(R) (sumatriptan injection) 3 mg and Tosymra(R) (sumatriptan nasal spray) 10 mg under a transition services agreement with Upsher-Smith Laboratories, LLC from whom the products were acquired on June 30, 2023. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. For more information about Tonix, visit www.tonixpharma.com.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

CEL-SCI Corporation (NYSE American: CVM), a phase 3 cancer-immunotherapy company, has closed on its previously announced public offering. The offering was comprised of 3,875,000 shares of common stock, offered at $2 per share, resulting in $7.75 million in gross proceeds before deducting underwriting discounts and offering expenses. According to the announcement, CEL-SCI anticipates using the funds for continued development of Multikine as well as for working capital and general corporate purposes. ThinkEquity acted as sole book-running manager for the offering.

To view the full press release, visit https://ibn.fm/kaEhi

About CEL-SCI Corporation

CEL-SCI believes that boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival. Multikine (leukocyte interleukin, injection) is designed to help the immune system “target” the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. In a phase 3 study, CEL-SCI studied patients who were newly diagnosed with locally advanced primary squamous cell carcinoma of the head and neck (oral cavity and soft-palate) with the investigational product Multikine administered first, before they received the standard of care, which involved surgery followed by either radiation or chemoradiation. The phase 3 study enrolled 928 patients. The company’s approach is unique because most other cancer immunotherapies are administered only after conventional therapies have been tried and/or failed. After analyzing data from the phase 3 study, the company has better defined the target population, which is advanced primary head and neck cancer patients with no lymph node involvement and with low PD-L1 tumor expression. In the phase 3 study, CEL-SCI observed statistically significant survival data in the final target population, showing that Multikine cut the risk of death in half at five years vs. control. The company plans to submit the proposed study protocol to the FDA in Q1 2024, with the goal to get FDA buy-in for a confirmatory clinical trial, and also to discuss potential accelerated approval pathways. Multikine received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. For more information about the company, please visit www.CEL-SCI.com.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Rocket Lab USA (NASDAQ: RKLB), a global leader in launch services and space systems, has closed on its private offering. The transaction was a $355 million principal amount of 4.250% convertible senior notes due 2029; the notes are due to those reasonably believed to be qualified institutional buyers. According to the announcement, the total amount of the offering comes from both the previously announced, upsized offering of $300 million combined with the full exercise of the $55 million option to purchase additional notes, which Rocket Lab granted to initial purchasers of the notes. The company anticipates using funds from the offering to repay a portion of its borrowings under its equipment financing agreement and for working capital or other general corporate purposes. “Closing today’s transaction is another exciting step for Rocket Lab as we continue our growth trajectory, and upsizing the offering due to oversubscription is a strong show of confidence,” said Rocket Lab founder and CEO Peter Beck in the press release. “This strategic move has added additional funding to the Rocket Lab balance sheet at what we view as the most attractive cost of capital available and least dilutive path for our existing shareholders. We look forward to deploying this capital efficiently and expediently towards a mix of opportunities including potential M&A and other strategic growth and scaling investments.”

To view the full press release, visit https://ibn.fm/bCZeT

About Rocket Lab USA Inc.

Rocket Lab is a global leader in launch and space systems. Rocket Lab’s Electron launch vehicle is the second most frequently launched U.S. rocket annually and has delivered more than 176 satellites to orbit for commercial and government partners, including NASA, the U.S. Air Force, DARPA and the NRO. Rocket Lab also delivers proven suborbital hypersonic launch capability with its HASTE launch vehicle. Building on the deep heritage of Electron, Rocket Lab is developing Neutron, an advanced 13-tonne payload class, reusable launch vehicle tailored for constellation deployment and interplanetary missions. Rocket Lab is also a premier supplier of advanced satellites, flight-proven subsystems and spacecraft components. At a component level, Rocket Lab spacecraft technology spans space solar power, composite structures, flight software, star trackers, reaction wheels, separation systems and more. Rocket Lab satellite technology and components have been integrated into more than 1,700 satellite missions globally. For more information about the company, please visit www.RocketLabUSA.com.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

DealFlow Events, renowned host and organizer of hundreds of investment themed conferences over the past two decades, today announced the Activist Investor Conference 2024. The leading forum for discussing governance-related issues relevant to investing professionals, the event is slated to take place on March 21, 2024, at Convene in New York City. First launched in 2010, DealFlow’s Activist Investor Conference 2024 provides unparalleled opportunities for professional education, networking and forging new business relationships. The event keeps focus on the industry’s most innovative and transformative ideas that enable investors to deepen their knowledge of governance issues and improve the fortunes of the companies in which they have invested. The conference will address several key themes of governance-related issues through engaging presentations and lively panel discussions.

To view the full press release, visit https://ibn.fm/xm7Fp

About DealFlow Events

DealFlow Events is widely recognized as a symbol of quality. For over two decades, DealFlow has created events that feature exclusive networking, education and business development opportunities. DealFlow Events has produced over 200 conferences, seminars and webcasts on a variety of financial topics. These events are the signature programs in their respective markets, offering high-quality content and professional networking opportunities. For more information, visit www.DealFlowEvents.com.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, has finalized three new contracts for its K1 Hemisphere. The contracts are with a commercial real estate company in California, a residential property in Illinois and a healthcare company in Minnesota.

Calling the K1 Hemisphere “a perfect entry point into deploying Knightscope’s combination of robotics and artificial intelligence (‘AI’) technologies,” the company noted that the Hemisphere is ideally suited to elevate the security and safety profile of any property.

“It can easily be mounted to a variety of surfaces or objects and has three cameras that provide up to 210 degrees of eye-level, high-definition video, a strobe light, automatic license plate recognition, facial recognition (optional), automated broadcast announcements and intercom capability running on a wired or fully encrypted wireless network,” the company stated in the press release. “Two Hemispheres can also be placed back-to-back for a 360-degree view.”

To view the full press release, visit https://ibn.fm/yfbST

About Knightscope, Inc.

Knightscope is an advanced public safety technology company that builds fully autonomous security robots and blue light emergency communications systems that help protect the places people live, work, study and visit. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Silo Pharma (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. The company today provided a positive update on SP-26, its novel time-released, dose-controlled formulation of ketamine initially targeted for fibromyalgia. According to the announcement, a pre-clinical research study is underway involving analytical testing services and small batch proof-of-concept extrusion trials to determine drug release and stability. In recent testing, SP-26 polymer implants were blended with ketamine hydrochloride (“ketamine HCL”) in two loadings, 20% and 40%, and the structural stability and integrity of both the loaded implants were maintained, with no leakage, degradation or discoloration. “Implantable drug delivery systems like SP-26 may provide sustained drug delivery for prolonged periods of time, which is critical for the treatment of chronic pain conditions,” said Eric Weisblum, CEO of Silo. “We believe the initial testing provided sufficient validation of the delivery system for SP-26 and accordingly, our focus has shifted to testing of the ketamine formulation to measure drug dissolution and time-release action.”

To view the full press release, visit https://ibn.fm/61w4w

About Silo Pharma Inc.

Silo Pharma is a developmental-stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions and central nervous system (“CNS”) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (“MS”). Silo’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Safety Shot (NASDAQ: SHOT) today announced that Matthew Espinosa joins Safety Shot as a brand ambassador to share his love and enthusiasm for the first patented wellness beverage on Earth that helps people feel better faster by reducing blood alcohol content, boosting clarity and overall mood. Having amassed more than 16 million followers across social media, Matthew is a multiplatform entertainer who has been catering to fans for the last 12 years. “Matthew’s highly entertaining and comedic content appeals to a generation of people that we believe will enjoy and benefit from Safety Shot as much as Matthew has,” said Safety Shot’s CEO Brian John. “We are super pleased to have him come on board as a brand ambassador and look forward to lots of media collaborations in which even more people will be exposed to our highly anticipated, in-demand wellness beverage.”

To view the full press release, visit https://ibn.fm/kf0gv

About Safety Shot Inc.

Safety Shot, a wellness and functional beverage company, is set to launch Safety Shot, the first patented wellness beverage on Earth that helps people feel better faster by reducing blood alcohol content, boosting clarity and overall mood. Safety Shot is available for retail purchase online at www.DrinkSafetyShot.com and www.Amazon.com. The company plans to launch business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars in the first quarter of 2024. Safety Shot plans to spin off legacy assets from its Jupiter Wellness business to unlock value for shareholders.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

DoubleDown Interactive (NASDAQ: DDI), a leading developer and publisher of digital games on mobile and web-based platforms, is reporting unaudited financial results for the fourth quarter and year ended December 31, 2023; that report includes contributions from European iGaming operator, SuprNation, which DoubleDown acquired in October 2023. Highlights of the report included $83.1 million revenue in the fourth quarter of 2023 compared to $76.2 million in the fourth quarter of 2022; a decrease in operating expenses, which totaled  $47.5 million in the quarter compared to $321.4 million in the same quarter in 2022; Adjusted EBITDA reached $36.2 million for Q4 2023, up from $24.7 million for Q4 2022; net income came in at $25.5 million for the quarter compared to a loss of $(194.4) million in the same quarter of 2022; average revenue per daily active user (“ARPDAU”) for DDI’s social casino/free-to-play games increased to $1.24 for the quarter, up from $0.98 in Q4 2022 and $1.06 in Q3 2023; and average monthly revenue per payer for the social casino/free-to-play games increased to $279 for the quarter of 2023.

“Our fourth-quarter results, which include a 3% year-over-year increase in core social casino revenue to $78.8 million and a 46% increase in Adjusted EBITDA to $36.2 million, highlight our best-in-class ability to monetize our loyal players combined with our disciplined approach to user acquisition and R&D spend which drives consistent profitability and strong free cash flow,” said DoubleDown CEO In Keuk Kim in the press release. “We continue to deliver strong engagement metrics for our flagship social casino game DoubleDown Casino, as ARPDAU and average monthly revenue per payer rose 26% and 23%, respectively, compared to the 2022 fourth quarter. As a result, cash flows from operating activities were approximately $30 million in the fourth quarter. . . . We place a primary focus on being capital efficient as reflected in our strong Adjusted EBITDA margins and free cash-flow generation. At 2023 year-end, cash and cash equivalents and short-term investments net of current borrowing were approximately $235 million, which is equivalent to approximately $4.75 per ADS. Our strong net cash position and consistent ability to generate attractive free cash flow provides the company with significant flexibility to evaluate further opportunities to deploy capital that would continue to expand our business in gaming categories with attractive addressable markets and where our operating discipline would ultimately deliver additional free cash flow and create new value for our shareholders.”

To view the full press release, visit https://ibn.fm/tz4cc

About DoubleDown Interactive Co. Ltd.

DoubleDown Interactive is a leading developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multiformat interactive entertainment experiences for casual players, bringing authentic Vegas entertainment to players around the world through an online social casino experience. DDI’s flagship social casino title, DoubleDown Casino, has been a fan-favorite game on leading social and mobile platforms for years, entertaining millions of players worldwide with a lineup of classic and modern games. Following its acquisition of SuprNation in October 2023, the company also operates three real-money iGaming sites in Western Europe. For more information about this company, please visit www.DoubleDownInteractive.com.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic treatment options, today announced unaudited financial results for its third quarter ended Dec. 31, 2023, and recent business highlights. “During the past three months, we have continued to make exciting progress with positive topline data from our CYB003 and DMT programs,” said Cybin CEO Doug Drysdale. “The data collected from our clinical trials forms the foundation of our next set of value-creating milestones, as we advance our key programs this year. For CYB003, the three-month Phase 2 efficacy data is expected in Q1 and will provide insights into the durability of treatment effect in MDD. Promising outcomes, such as a 79% remission from depression at 6 weeks in our Phase 2 CYB003 trial, and important safety and dosing findings in our Phase 1 dDMT studies, validate our path forward. Plans are underway to initiate a Phase 3 multisite trial of CYB003 for MDD, and with FDA clearance, we are progressing to a Phase 2a study of CYB004 for the treatment of GAD. We are proud of the rapid progress we have made and look forward to the important work ahead of us. We are encouraged by the positive findings across our clinical-stage programs to date and believe we are well on our way to providing more effective and patient-friendly treatment alternatives for a multitude of mental health disorders.”

To view the full press release, visit https://ibn.fm/XKTPw

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental health care is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, is reporting its Q3 2024 financial numbers as well as providing an update on the company. Notable numbers from the report include research and development expenses reaching $4.5 million and $6.9 million for the three months ended Dec. 31, 2023 and 2022, respectively; general and administrative expenses for the 2023 quarter totaled $3.8 million, up from $3.1 million in 2022; and net loss reached $6.3 million for 2023, down from $9.8 million 2022. The company also reported cash and cash equivalents of some $126.6 million, with 27,029,731 shares of common stock issued and 3,577,240 prefunded warrants outstanding as of Feb. 12, 2024. The report noted that VTGN’s fasedienol PALISADE phase 3 programs for the acute treatment of social anxiety disorder (“SAD”) remains on track and the company is planning on starting a PALISADE-3 trial and PALISADE-4 trial in 2024.

“Momentum from clinical and corporate milestones achieved through the end of last quarter have significantly advanced our efforts to develop and commercialize fasedienol as a potential first-in-class acute treatment for adults with social anxiety disorder,” said Vistagen Therapeutics CEO Shawn Singh in the press release. “Building on the positive results of our PALISADE-2 phase 3 trial in SAD, we remain on track to initiate our PALISADE-3 phase 3 trial in SAD during the first half of this year. In parallel, we continue to make significant progress toward phase 2B development of two additional clinical-stage neuroscience assets in our pipeline, itruvone for major depressive disorder and hormone-free PH80 for women’s health indications, including vasomotor symptoms (hot flashes) due to menopause.”

To view the full press release, visit https://ibn.fm/1wRLt

About Vistagen Therapeutics Inc.

Vistagen is a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders. Five of Vistagen’s six clinical-stage product candidates belong to a new class of drugs known as pherines, which have the potential to rapidly deliver meaningful efficacy with a differentiated safety profile. Pherines are investigational neuroactive nasal sprays with innovative proposed mechanisms of action that activate chemosensory neurons in the nasal passages to impact fundamental neural circuits in the brain without the need for systemic absorption or binding to receptors in the brain. Vistagen’s sixth clinical-stage product candidate, AV-101, is an investigational oral drug candidate with the potential to inhibit but not block NMDA receptor activity. Vistagen is passionate about transforming what is possible in the treatment of anxiety, depression and other neuroscience disorders For more information about the company, please visit www.Vistagen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Tonix Pharmaceuticals Holding (NASDAQ: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, recently held a key opinion leader (“KOL”) webinar hosted by Alliance Global Partners (“AGP”). The webinar featured two thought leaders in the field of fibromyalgia, Dr. Daniel Clauw and Dr. Lesley Arnold. The thought leaders discussed the positive data from a Phase 3 study of Tonmya(TM) (also known as TNX-102 SL, cyclobenzaprine HCI sublingual tablets) for the management of fibromyalgia and the path to file an NDA for FDA approval in H2 2024. According to the announcement, clinical results show that Tonmya(TM) has broad-spectrum activity, addressing the three core fibromyalgia symptoms: pain, fatigue, and sleep disturbance. In addition, Tonmya(TM) has a favorable tolerability profile that is well-suited for chronic treatment.

“We believe that these positive results show that fibromyalgia can be successfully treated by Tonmya(TM) and may provide the opportunity for Tonix to have the first FDA-approved drug for fibromyalgia in more than a decade,” commented Seth Lederman, M.D., President and CEO of Tonix. “We are now an important step closer to bringing a new, first-line treatment to fibromyalgia patients that offers broad symptom relief and favorable tolerability for chronic use and adherence.”

To view the webinar, visit https://ibn.fm/bYe54

To view the full press release, visit https://ibn.fm/LMhXU

About Tonix Pharmaceuticals Holding Corp.

Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system disorders. Tonix’s priority is to submit a New Drug Application (“NDA”) to the FDA for Tonmya, which has completed two positive Phase 3 studies for the management of fibromyalgia. Tonix intends to meet with the FDA in the first half of 2024 and submit an NDA for the approval of Tonmya for the management of fibromyalgia in the second half of 2024. TNX-102 SL is being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition, and topline results from a proof-of-concept study were reported in the third quarter of 2023. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the first quarter of 2024. Tonix’s rare disease development portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome (“PWS”). TNX-2900 has been granted Orphan Drug designation by the FDA and an investigational new drug (“IND”) application has been cleared to support a Phase 2 study in PWS patients. Tonix’s immunology development portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (“CD40L” or “CD154”) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-801 was initiated in the third quarter of 2023. Tonix’s infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800, in development as a vaccine to protect against COVID-19. During the fourth quarter of 2023, TNX-1800 was selected by the U.S. National Institutes of Health (“NIH”), National Institute of Allergy and Infectious Diseases (“NIAID”) Project NexGen for inclusion in Phase 1 clinical trials. The infectious disease development portfolio includes TNX-3900 and TNX-4000, which are classes of broad-spectrum small molecule oral antivirals. Tonix Medicines, the company’s commercial subsidiary, markets Zembrace(R) SymTouch(R) (sumatriptan injection) 3 mg and Tosymra(R) (sumatriptan nasal spray) 10 mg under a transition services agreement with Upsher-Smith Laboratories, LLC from whom the products were acquired on June 30, 2023. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. For more information about Tonix, visit www.tonixpharma.com.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

DealFlow Events, host and organizer of hundreds of investment themed conferences over the past two decades, today announced the 2nd Annual Venture Debt Conference 2024. As the world’s largest forum dedicated to non-dilutive financing strategies for emerging growth companies, the event is slated to take place on March 6, 2024, at the historic Edison Ballroom in New York City. The full-day forum will focus on the growing role of venture debt and the varied forms of financing that minimize ownership dilution, offering unique networking opportunities and in-depth strategy discussions for VC-backed and emerging growth companies. Attendees will glean insights into the most cutting-edge products and services in the alternative financing space, such as term loans, revenue-based, receivables and equipment financing. The Venture Debt Conference 2024 will feature product information and education while also shedding light on current market dynamics, the changing nature of lending and evolving client needs.

To view the full press release, visit https://ibn.fm/g30QG

About DealFlow Events

DealFlow Events is widely recognized as a symbol of quality. For over two decades, DealFlow has created events that feature exclusive networking, education and business development opportunities, DealFlow Events has produced over 200 conferences, seminars and webcasts on a variety of financial topics. These events are the signature programs in their respective markets, offering high-quality content and professional networking opportunities. For more information, visit www.DealFlowEvents.com.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Optec International (OTC: OPTI) is the focus of a judgment filed by California-based RB Capital Partners Inc., a private investment fund. A recent announcement noted that RB Capital was clarifying the judgment and releasing a shareholder update. According to the announcement, RB Capital observed that it was the largest investor and legitimate shareholder of OPTEC and was “forced to bring a shareholder derivative action against the company to secure our judgment, oust the failing [CEO] Roger Pawson and to try to preserve the assets of the company.” RB Capital filed the lawsuit, noting that Pawson used the company for self-dealing and mismanaged the operations of the corporation at the expense of the shareholders. The judgment was secured in November 2023; the judgment amount was $11.5 million interests and costs, which totaled $14,681,270.50 against Pawson and Optec jointly and severally.

“The court’s judgment also prohibits Pawson from serving as a director and/or CEO of Optec; prohibits Pawson from issuing any class of stock of Optec or transferring any assets of Optec to himself or any third party; prohibits Pawson from using Optec’s assets for his personal gain and to return all ill-gotten funds back to Optec, and finally, the court authorized RB Capital Partners Inc, upon application to the court, to appoint a receiver to control Optec and its assets,” said RB Capital Partners in the press release. “To date we have not sought the appointment of a receiver as we weigh the benefits of doing so, and RB Capital Partners Inc., nor any of its members, are an officer or director of Optec International Inc.”

To view the full press release, visit https://ibn.fm/cu4WL

About RB Capital Partners Inc.

RB Capital Partners is a private investment fund headquartered and incorporated in California. The main investment focus of RB Capital is on small and microcap publicly traded companies trading on the OTC Markets, NASDAQ & New York Stock Exchange. RB Capital predominantly makes debt investments and is known for paying off harmful or convertible debt, giving companies a real chance of success. RB Capital Partners does not manage any outside money nor does it have any investors. It is run and funded solely by Brett Rosen and Deborah Rosen, who each have a 50% ownership stake in the company.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN